| Accession |
PRJCA011231 |
| Title |
PHYSIOLOGICAL BASED PHARMACOKINETIC (PBPK) MODELING OF PYROTINIB TO UNDERSTAND THE INTERPLAY BETWEEN CYP3A4 AND P-GP WHEN CO-ADMINISTRATED WITH CYP3A4 INHIBITORS/INDUCERS |
| Relevance |
Medical |
| Data types |
PK
|
| Organisms |
Homo sapiens
|
| Description |
Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for treating HER2-positive advanced solid tumors. CYP3A4 primarily metabolizes Pyrotinib, and in vitro assay suggested a potential substrate for P-gp efflux transporter. The objective was to use the PBPK model of pyrotinib to understand how the interplay of CYP3A4 and P-gp can affect the drug-drug interactions (DDI) for pyrotinib when co-administered with CYP3A4 inhibitors/inducers. |
| Sample scope |
Multiisolate |
| Release date |
2024-08-16 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Jiangsu Hengrui Pharmaceutical Co., Ltd
|
|
NA
|
|
|
|
| Submitter |
miao
wang (miao.wang.mw5@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co., Ltd |
| Submission date |
2022-08-16 |
